Sales Growth YoY (Last Twelve Months): Pluri Inc. (PLUR)

Graphic logo of Pluri (PLUR)

The creation of a cellular production ecosystem and the integration of a 3D platform into the bio-industry are scaling the business, which is why the rolling 12-month YoY revenue growth chart on GURU.Markets places the metric value at 9.90. Pluri Inc. (PLUR) maintains a scientific priority through leadership in regenerative medicine via cell-growth innovations, while a strong team of Israeli researchers ensures the stability of the company's human capital potential.

Sales Growth YoY (Last Twelve Months): pluri-biotech.com (PLUR) for 02/11/2024 - 11/18/2026

Summary analytical data breakdowns for Pluristem Therapeutics (PLUR)

- market value and analyst target forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Pluristem Therapeutics (PLUR)
Mass-produced product of Pluri

Pluri Inc. is scaling the commercialization of biomass for synthetic meat and medicine. Revenue dynamics over the last 12 months are calculated as the percentage deviation of current aggregate income from the same period last year. This metric assesses the viability of the business model amid volatile demand for 3D cellular technologies. It is critical for investors to track the expansion rate of the customer base. Relative revenue growth over four quarters compared to the previous year visualizes the pace of this expansion.

Competitor analysis for Pluri Inc.

Ascendis (ASND) - Trailing Twelve Months Revenue Growth|MDGL - Sales Growth YoY (Last Twelve Months)|CORT: Sales Growth YoY (Last Twelve Months)|RYTM: Sales Growth YoY (TTM)|AKRO - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Metsera Therapeutics|MoonLake Corp (MLTX) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) crinetics.com (CRNX)|Revenue Growth YoY (Last 12 Months) newamsterdampharma.com NAMS|Sales Growth YoY (Last Twelve Months) Soleno Therapeutics Inc SLNO|Sales Growth YoY (TTM) Amicus Therapeutics Inc FOLD|89bio Corp - Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Agios Pharmaceuticals Inc (AGIO)|Structure Therapeutics (GPCR) - Sales Growth YoY (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) MiMedx Group, Inc.|Sales Growth YoY (Last Twelve Months) Rezolute Bio|Lexicon Pharmaceuticals, Inc. (LXRX) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (TTM) MBX|Revenue Growth YoY (Last 12 Months) Altimmune, Inc. ALT|Sales Growth YoY (TTM) AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Trailing Twelve Months Revenue Growth|BIOA: Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) BMEA (Biomea Fusion)|QNCX (quincetx.com) - Revenue Growth YoY (Last 12 Months)|Fractyl - Revenue Dynamics YoY (Last Twelve Months)|VTVT (vTv Therapeutics Inc) - Sales Growth YoY (TTM)|Agape ATP - Trailing Twelve Months Sales Growth|Sales Growth YoY (TTM) SYBX|Annual Revenue Growth (Last Twelve Months) Lipocine Inc|Sales Growth YoY (Last Twelve Months) Matinas BioPharma Holdings MTNB|Annual Revenue Growth (Last Twelve Months) Spruce Biosciences (SPRB)|GLTO: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Sales Growth CTCX|LUMO (Lumos Pharma) - Revenue Growth YoY (Last 12 Months)|Sales Growth YoY (Last 12 Months) ONVO|RDUS (Radius Pharmaceuticals) - Sales Growth YoY (TTM)